Beyond Biotech - the podcast from Labiotech

Labiotech
  • 3,3 (3)
  • НОВОСТИ ТЕХНОЛОГИЙ
  • ЕЖЕНЕДЕЛЬНО

Welcome to the official Labiotech.eu podcast - Beyond Biotech! Each week, we talk about what's happening in the world of biotech, with news and interviews with experts from companies around the world. Join us as we cover the latest news, breakthroughs and innovations shaping the life sciences industry.A new podcast episode is available every Friday. The host is Dylan Kissane.

  1. -6 ДН.

    AION Labs is building innovative biotechs with top pharma partners in Israel

    How can you guarantee that top pharma will be interested in investing in your biotech startup? How can you be sure that the target you are focused on will be attractive to industry partners? And can AI help drive this interest and deliver these partnerships? These are questions that this week’s guest, Mati Gill, CEO of AION Labs in Israel, is perfectly positioned to answer. AION Labs has an innovative company creation process that empowers scientists and startups to tackle high-impact pharma challenges with AI, backed by top-tier data, funding, and expertise from global pharma partners. In the middle of a transformative decade for AI-driven drug discovery, and with Israel poised to play an increasingly significant part, Mati explains how venture studios are helping to foster groundbreaking solutions for global health challenges. 01:07               Meet Mati Gill 07:19               The biotech industry in Israel 09:38               How the Israeli biotech industry is changing with AI and other technologies 13:01               The biggest challenges facing Israeli biotechs and biopharma 18:07               AION Labs and its mission 20:27               AION Building and AION Seeding 24:03               Why top pharma wants to partner with AION Labs startups 27:53               Workshopping startup ideas with top pharma companies 32:04               The future of venture studios like AION Labs 36:33               At the intersection of AI, biotech, and Israel’s innovation ecosystem 39:24               Advice for entrepreneurs and scientists Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!  Stay updated by subscribing to our newsletter To dive deeper into the topic:  AION Labs launches AI startup to improve drug trialsThe 5 hottest biotech companies making waves in IsraelWhat to look for in a biotech incubator

    42 мин.

  2. 5 СЕНТ.

    Navigating the biotech development journey from first steps to global scale with Lonza

    Lonza is one of the world’s largest contract development and manufacturing organizations (CDMOs), dedicated to serving the healthcare industry. They work alongside a broad range of customers – from emerging biotechs to top global pharmaceutical companies – to transform therapeutic discoveries into life-saving and life-enhancing treatments for their patients.  Founded in 1897 in the Swiss Alps, Lonza has embraced innovation and kept pace with a fast-changing world for more than 125 years. They are a leader in both established and emerging technologies and today their 19,000 employees across more than 30 sites on five continents generate annual sales of more than $4.4 billion.  We sat down with Alice Harrison, Global Technical Director (CMC and Analytics), and Megan Mason, Global Process Development Implementation Manager, to learn more about how Lonza is helping innovators large and small develop and scale their therapies and deliver better outcomes for patients worldwide. _____ The information in this podcast is believed to be correct at the time of recording, and is for information only. While we make reasonable efforts to ensure that the content is accurate, we make no representations or warranties of any kind regarding its accuracy, completeness, reliability, suitability or the results to be obtained from the use of such information. Lonza disclaims any liability for the use of this information and the reliance of the information contained herein is at your own risk.   _____ Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!  Stay updated by subscribing to our newsletter To dive deeper into the topic:  How to Set up Manufacturing for Biotech StartupsAccelerating the path to clinical filing applications with rapid toxicology material deliveryLarge molecule manufacturing: addressing challenges with strategies for success

    51 мин.

  3. 29 АВГ.

    A Finnish biotech is making progress on Parkinson's disease with support from The Michael J. Fox Foundation

    Parkinsons disease impacts some 10 million people worldwide and current approaches to treating the condition almost exclusively focus on addressing symptoms – there is, as of yet, no cure. One Finnish biotech, however, is not focused on alleviating symptoms but on modifying the course of the disease itself. Their hope is to be able to stop and even reverseneurodegenerative diseases like Parkinsons, and they have the backing of significant players, such as the Michael J Fox Foundation, to do just that. This week I spoke to Antti Vuolanto, CEO of Herantis Pharma, about the work his company is doing, the science behind their approach, and the advantages and challenges of working in biotech in the Nordics. 01:10               Meet Antti Vuolanto 05:10               The biotech landscape in the Nordics 07:07               Herantis Pharma and its mission 09:38               Treating symptoms versus disease modification 13:31               Herantis in relation to other Parkinson’s disease companies 15:47               HER-096 26:24               The global burden of Parkinson’s disease and the unmet need 28:56               The role of patient and advocacy groups 30:11               The future of Parkinson’s disease treatment 31:52               How the Nordics can develop and expand their biotech sector 36:33               Stay up to date on Herantis and their work Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!  Stay updated by subscribing to our newsletter To dive deeper into the topic:  Finland: Pushing biotech forward in the land of a thousand lakesParkinson’s disease: biotech’s pursuit for more therapies The stem cell race for Parkinson’s disease: Recent studies show significant promise

    38 мин.

  4. 22 АВГ.

    How RNAi is expanding from a therapy of choice for rare disease into treating common conditions

    RNAi has changed the way that rare diseases are treated - is it about to do the same for more common conditions? Alnylam was the very first company to translate RNAi from Nobel Prize winning science into a commercially scalable platform. Founded in 2002, the company today has five different RNAi therapies on the market and a pipeline that continues to expand. While their early focus was on rare disease, today they are expanding into more common conditions, partnering with top pharma companies to bring next-generation therapies to market. This week I sat down with Paul Nioi, Senior Vice President of Research at Alnylam. Paul has more than 20 year’s experience in biotech and biopharma, and he walked me through Alnylam’s mission and place in the biotech ecosystem, the science of RNAi, the early success treating metabolic disease, and exactly where their platform is expanding into now and in the near future. Paul explains the capacity of RNAi to address neurological and infectious disease, the value of large-scale genomic initiatives, and how he sees drug discovery evolving in the years ahead. 01:29               Meet Paul Nioi 08:56               Alnylam, its mission, and its science 14:35               Two types of partnerships: top pharma, and genomic initiatives 22:34               RNAi therapies on the market for rare disease 27:29               Expanding into more common conditions 32:17               INHBE mutations and cardiometabolic disease 35:01               Working with Roche to target hypertension 38:58               Looking forward: Alnylam’s platform in the near future 41:49               What role for national genomic initiatives? 45:16               RNAi’s place in a future of precision medicine Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!  Stay updated by subscribing to our newsletter To dive deeper into the topic:  mRNA, RNAi, circRNA, ASOs: A comparative guide to RNA therapeuticsSix biotech companies leading the charge in hemophilia treatmentEpisode 159: Day One DNA - How and why the UK is betting on whole genome sequencing for every newborn

    48 мин.

  5. 15 АВГ.

    Are next-generation psychedelics the way forward for addressing treatment resistant depression?

    Nearly 1 billion people around the world suffer from mental health disorders, with the global economic cost of those disorders expected to reach $6 trillion by 2030.  One of the most common of those mental health disorders is depressive disorder, commonly called depression, with some 280 million people suffering from either mild, moderate or severe depression. Conventional treatments for depression such as selective serotonin reuptake inhibitors, or SSRIs, can work for many people but for some suffering from treatment resistant depression, options can be limited, but some new therapies are in the clinic and might offer some hope.  Beckley PsyTech is a UK biotech that is working with next-generation psychedelic-based compounds administered in a short clinic visit once every two months. With positive results from their recent Phase 2B study and a partnership with atai Life Sciences, Beckley believes they are on their way to redefining how depression is treated. 01:38               Meet Cosmo Feilding 03:04               Beckley PsyTech, its mission and its focus 08:36               BPL-003 and next generation psychedelics 11:16               Intranasal delivery and its advantages 14:26               Psychedelics in the clinic and Phase IIb trial results 18:32               Safety: suicide signals and adverse events 21:02               Applications for psychedelics outside of depression 24:11               The global economic costs of mental health disorders 27:40               Comparing Beckley PsyTech to Compass Pathways and GH Research 35:26               Regulatory hurdles and the stigma around psychedelics 38:14               Partnering with atai Life Sciences and the future of Beckley PsyTech 43:16               Milestones ahead for Beckley PsyTech 45:44               A future vision for patients suffering from depression Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!  Stay updated by subscribing to our newsletter To dive deeper into the topic:  New antidepressants: tackling treatment resistant depressionPsychedelics sans side effects: neuroplastogens gain groundFrom LSD to healing minds: Where are we standing in psychedelic drug development?

    49 мин.

  6. 8 АВГ.

    Day One DNA: How and why the UK is betting on whole genome sequencing for every newborn

    The UK is preparing to change the game for healthcare - but why, how, and what will it cost? Recently the UK government announced plans to sequence the DNA of every baby born in that country. A part of the country’s 10 Year Health Plan, the program aims to identify rare genetic diseases early, prevent harms from delayed treatment and reduce future healthcare costs for the NHS. Yet along with those potential upsides come a range of ethical and practical questions, too: who guards the sequenced data, who can access it, how can consent be informed, managed and withdrawn years later, and what is the best way to gather the genetic material required to fully sequence the DNA of 700,000 infants each year? This week, I spoke to Neil Ward of PacBio to understand more about this program, compare it to other national genome sequencing programs in Europe and Asia, and discuss the promise of unlocking the ‘language of life’. 02:02               Meet Neil Ward 09:10               PacBio, its mission, and its current focus 17:13               The UK national newborn gene sequencing effort 21:20               Ethical and practical challenges for national newborn sequencing 24:34               Short-read versus long-read sequencing 30:48               Dried blood spots versus cord blood 35:57               Lessons for the UK from Thailand 38:58               Trends in national newborn screening programs worldwide 41:46               What parents and policymakers must know 45:20               Exciting things in the genomics space on the horizon This episode is brought to you by MedChemExpress. Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!  Stay updated by subscribing to our newsletter To dive deeper into the topic:  The past, present, and future of genome sequencingThe next frontier in genomic technologies for rare diseasesSeven genome sequencing companies to look out for

    50 мин.

  7. 1 АВГ.

    Meatly's innovative cultivated meat is already delighting pets, are humans next?

    Is cultivated meat the future of pet food? And is there a place for cultivated meat on human dinner tables, too? Traditional agricultural methods are slow, require large tracts of land, significant energy and environmental inputs, and – somewhat obviously – the slaughter of hundreds of millions of animals every year. Cultivated meat – that is meat that is grown in a lab – requires little land, less energy, and in the case of Meatly, nothing more than a single cell from a single chicken egg, once.  This week I sat down with Owen Ensor, CEO of UK biotech startup Meatly, to talk all things cultivated meat. He explains the science behind his company’s cultivated meat process, the significant cost savings that Meatly has made to bring down prices for their product, and how his company became the very first in Europe to have a cultivated meat product approved for sale, in the hands of consumers, and in the bellies of beloved cats and dogs. 01:29               Meet Owen Ensor 05:10               Meatly and its mission 10:12               The science of cultivated meat 19:41               Common criticisms of cultivated meat 25:33               Regulation, and geographical diversity in regulation 32:24               Looking forward: from pets to human consumption? Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!  Stay updated by subscribing to our newsletter To dive deeper into the topic:  Cultured Meat Is Coming Soon: Here’s What You Need to Know10 cultured meat companies driving sustainable food in 2025The future of food: what’s behind the cell-cultured meat industry regulations?

    39 мин.

  8. 25 ИЮЛ.

    Cryoport Systems on the state of the ATMP market and the importance of supply chain resilience

    With supply chain management and optimization, risk management, and the capacity to address global markets efficiently and effectively top of mind for all growing biotechs, I'm excited to be joined by Alison Pritchard, Vice President, Business Development at Cryoport Systems, to learn more about how they support life science innovators worldwide. Cryoport Systems evolved alongside the life science  industry and expanded its capabilities into full-scale supply chain management solutions that support the critical journeys of the biopharmaceutical, reproductive medicine, and animal health markets. In this episode we look at the ATMP market, the regulatory landscape in EMEA, and the importance of supply chain resilience for cutting edge therapies, whether from established pharmaceutical companies or emerging biotechs and startups. 00:02:14   The state of the ATMP market in 2025 00:07:20    Regulatory trends in EMEA 00:13:53    Operational and supply chain challenges 00:22:13    Lessons in supply chain resilience 00:28:56   Outsourcing trends in biotech 00:37:34    Geopolitical influences on the ATMP supply chain 00:40:39    Cryoport Systems' plans for the future 00:45:53    Final word Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!  Stay updated by subscribing to our newsletter To dive deeper into the topic:  Cracking the code: Delivering biotherapeutics successfully across EMEAUnlocking consistency in ATMP development: How cryopreservation strengthens Europe’s cell therapy supply chain

    49 мин.
См. все (164)

Оценки и отзывы

3,3
из 5
Оценок: 3

Об этом подкасте

Welcome to the official Labiotech.eu podcast - Beyond Biotech! Each week, we talk about what's happening in the world of biotech, with news and interviews with experts from companies around the world. Join us as we cover the latest news, breakthroughs and innovations shaping the life sciences industry.A new podcast episode is available every Friday. The host is Dylan Kissane.

Информация

  • Автор
    Labiotech
  • Годы выхода
    2022 - 2025
  • Выпуски
    164
  • Ограничения
    Без ненормативной лексики
  • Авторские права
    © 2025 Beyond Biotech - the podcast from Labiotech
  • Сайт подкаста
    Beyond Biotech - the podcast from Labiotech

Вам может также понравиться